Posted on 10/07/21
| News Source: Times of Israel
A new Israeli studies has found the risk of heart inflammation as a result of Pfizer’s coronavirus vaccine to be exceedingly low and eminently treatable.
A link has been seen in recent months between coronavirus vaccines using mRNA technology and very rare cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart).
Research conducted by Israel’s largest healthcare provider, Clalit, along with Beilinson Medical Center, and published Wednesday in The New England Journal of Medicine, examined data on 2.5 million vaccinated Israelis, 94% of which had received two doses of the vaccine.
It found that cases of such inflammation occurred in 54 people (51 men, three women) or 2.13 of every 100,000 vaccinees (some two thousands of a percentage point). Of those, 98 percent of cases were mild (76%) to moderate (22%) and did not cause any damage to heart function. A single person of the 2.5 million experienced a severe case that required hospitalization, and went on to recover, the study found.
When it does occur, the heart inflammation side effect has particularly been seen in younger males, after their second dose. The new study bore that out, with 69% of cases occurring after the second shot, mostly in males and mostly in the 16-29 age group (where case prevalence was 10.7 for every 100,000).